{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:58Z","timestamp":1791245218700,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>This study assessed the real-world effectiveness of immunoglobulin replacement therapy (IgRT) for treatment of hypogammaglobulinemia and infections in patients with multiple myeloma (MM). A retrospective study was conducted on adult patients diagnosed with MM on or after 1 January 2010 using the Mass General Brigham Research Patient Data Registry. Infections were compared before and after IgRT initiation. Generalized estimating equation logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). In patients with accessible serum protein electrophoresis (SPEP) test results, a Natural Language Processing program supported the extraction of immunoglobulin G (IgG) data. The IgG assessments and incidence of hypogammaglobulinemia (defined as IgG level &amp;lt;500 mg\/dL) were compared before and after IgRT initiation. The results were reported using descriptive statistics. A total of 6062 patients with MM were identified (56.2% male; median age, 65.0 years). Of the 6062 patients, 471 (7.8%) received \u22651 IgRT administrations. At 3 months, significantly lower odds of infections (OR, 0.71; 95% CI, 0.56-0.89; P = .0004) were observed after IgRT initiation than before IgRT. Among patients with accessible SPEP results (n = 3405), 3231 (94.9%) underwent \u22651 IgG test with a median of 18.0 (interquartile range, 7.0-40.0) IgG tests per patient. Hypogammaglobulinemia was experienced by 2075 of the 3231 patients (64.2%) who had \u22651 IgG test. Significantly fewer patients had hypogammaglobulinemia after IgRT initiation. In conclusion, IgRT use was associated with significant reductions in hypogammaglobulinemia and infections. Although IgRT is currently used for MM treatment, there is potential to optimize its dosing and treatment duration to reduce the morbidity and mortality associated with infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015477","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T21:14:56Z","timestamp":1746047696000},"page":"3780-3789","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4042-1526","authenticated-orcid":false,"given":"Elizabeth","family":"O\u2019Donnell","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5263-1283","authenticated-orcid":false,"given":"Thais","family":"Gift","sequence":"additional","affiliation":[{"name":"3Takeda Pharmaceuticals USA, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-2108","authenticated-orcid":false,"given":"Zaid","family":"Yousif","sequence":"additional","affiliation":[{"name":"4Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Khandelwal","sequence":"additional","affiliation":[{"name":"3Takeda Pharmaceuticals USA, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Desai","sequence":"additional","affiliation":[{"name":"5Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[{"name":"5Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Clear","sequence":"additional","affiliation":[{"name":"5Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Pinaire","sequence":"additional","affiliation":[{"name":"5Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchen","family":"Ye","sequence":"additional","affiliation":[{"name":"5Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3464-4897","authenticated-orcid":false,"given":"Azeem","family":"Banatwala","sequence":"additional","affiliation":[{"name":"5Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Belsky","sequence":"additional","affiliation":[{"name":"6Department of Research Information Science and Computing, Mass General Brigham, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichuan Grace","family":"Hsieh","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, MA"},{"name":"6Department of Research Information Science and Computing, Mass General Brigham, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Herrick","sequence":"additional","affiliation":[{"name":"6Department of Research Information Science and Computing, Mass General Brigham, Somerville, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"5Analysis Group, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn N.","family":"Murphy","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, MA"},{"name":"6Department of Research Information Science and Computing, Mass General Brigham, Somerville, MA"},{"name":"7Department of Neurology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Sanchirico","sequence":"additional","affiliation":[{"name":"3Takeda Pharmaceuticals USA, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2025081209363721700_bib1","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025081209363721700_bib2","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Myeloma. Available at:. Accessed 26 June 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"issue":"Supplement 1","key":"2025081209363721700_bib3","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1182\/blood-2022-171155","article-title":"Race-Specific Mortality from Multiple Myeloma: A CDC Database Population Study in the United States between 2000 and 2020","volume":"140","author":"Al Zubaidi","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2025081209363721700_bib4","doi-asserted-by":"crossref","first-page":"14564","DOI":"10.1038\/s41598-024-65590-4","article-title":"Multiple myeloma incidence and mortality trends in the United States, 1999-2020","volume":"14","author":"Zhu","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"2025081209363721700_bib5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity","volume":"125","author":"Rosenberg","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2025081209363721700_bib6","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12885-021-08451-x","article-title":"Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019","volume":"21","author":"Balmaceda","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"2025081209363721700_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"2025081209363721700_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025081209363721700_bib9","doi-asserted-by":"crossref","first-page":"1098326","DOI":"10.3389\/fonc.2023.1098326","article-title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review","volume":"13","author":"Jolles","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"2025081209363721700_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"issue":"15","key":"2025081209363721700_bib11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2217\/imt-2022-0142","article-title":"Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections","volume":"14","author":"Lahue","year":"2022","journal-title":"Immunotherapy"},{"issue":"6","key":"2025081209363721700_bib12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2025081209363721700_bib13","first-page":"Cd006501","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation","volume":"2008","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2025081209363721700_bib14","unstructured":"NCCN. Multiple Myeloma. V4. 2024. Accessed 12 September 2024. https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/12\/article-p1281.xml."},{"issue":"2","key":"2025081209363721700_bib15","doi-asserted-by":"crossref","first-page":"e000734","DOI":"10.1136\/jitc-2020-000734","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma","volume":"8","author":"Shah","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2025081209363721700_bib16","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"20","key":"2025081209363721700_bib17","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"key":"2025081209363721700_bib18","doi-asserted-by":"crossref","first-page":"e930241","DOI":"10.12659\/MSM.930241","article-title":"Secondary Immunodeficiency and Hypogammaglobulinemia with IgG Levels of &lt;5 g\/L in Patients with Multiple Myeloma: A Retrospective Study Between 2012 and 2020 at a University Hospital in China","volume":"27","author":"Ye","year":"2021","journal-title":"Med Sci Monit"},{"issue":"16","key":"2025081209363721700_bib19","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1182\/bloodadvances.2024013073","article-title":"IgG Testing, Immunoglobulin Replacement Therapy, and Infection Outcomes in Patients with CLL or NHL: Real-World Evidence","volume":"8","author":"Soumerai","year":"2024","journal-title":"Blood Adv"},{"key":"2025081209363721700_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno","year":"2014","journal-title":"Front Immunol"},{"issue":"24","key":"2025081209363721700_bib21","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2025081209363721700_bib22","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/j.jtct.2023.12.272","article-title":"Incidence, Characteristics, and Management of Adverse Events with Bispecific T Cell Engagers for Relapsed or Refractory Multiple Myeloma: A Systematic Review","volume":"30","author":"Faiz","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2025081209363721700_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2025081209363721700_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.HS9.0000829556.56345.01","article-title":"B04: Combination of subcutaneous teclistamab with daratumumab in patients with relapsed\/refractory multiple myeloma (RRMM): Results from a phase 1B multicohort study","volume":"6","author":"Rodriguez-Otero","year":"2022","journal-title":"HemaSphere"},{"issue":"5","key":"2025081209363721700_bib25","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.clml.2020.12.026","article-title":"Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma","volume":"21","author":"Lancman","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2025081209363721700_bib26","first-page":"5187","article-title":"Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections","volume":"30","author":"Link","year":"2022","journal-title":"Support Care Cancer"},{"issue":"14","key":"2025081209363721700_bib27","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1080\/10428194.2021.1961233","article-title":"Infections in secondary immunodeficiency patients treated with Privigen or Hizentra: a retrospective US administrative claims study in patients with hematological malignancies","volume":"62","author":"Mallick","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025081209363721700_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2042098614554919","article-title":"Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem","volume":"5","author":"Llor","year":"2014","journal-title":"Ther Adv Drug Saf"},{"key":"2025081209363721700_bib29","first-page":"20499361211036773","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3780\/2403996\/blooda_adv-2024-015477-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3780\/2403996\/blooda_adv-2024-015477-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:36:46Z","timestamp":1755005806000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/3780\/537056\/Real-world-effectiveness-of-immunoglobulin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":29,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015477","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,7,25]]}}}